Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumazenil in Hepatic Encephalopathy
NCT02048969Phase 2Withdrawn
- Sponsor
- Yale University
- Start
- Jun 2014
- Primary completion
- Oct 2017
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of flumazenil in hepatic encephalopathy (HE), sponsored by Yale University. Planned start Jun 2014; status: withdrawn.
02
Drugs
flumazenil
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT02048969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048969.